Reason, co-founder and CEO of Repair Biotechnologies and a longevity industry veteran with a background in astrophysics, joins us to talk about what it actually takes to test a therapy on humans, and why the system built to protect patients often keeps the best evidence hidden.
He breaks down why investors backing gene and cell therapies care more about a drug’s earning potential than whether it works, and why treatments already in use could be quietly adding years to human lifespan without anyone confirming it. Drawing on his own experience as a trial participant in Roatán, he also explains why Australia has become a faster, cheaper alternative for clinical trials, and how much of that gap comes down to culture rather than actual safety.
More about Reason’s work:
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.